Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome

被引：20
作者：
Brackbill, Marcia L. [1 ,2 ]
Kidd, Robert S. [4 ]
Abdoo, April D. [1 ]
Warner, James G., Jr. [2 ]
Harralson, Arthur F. [3 ]
机构：
[1] Shenandoah Univ, Bernard J Dunn Sch Pharm, Dept Pharm Practice, Winchester, VA 22601 USA
[2] Winchester Med Ctr, Heart & Vasc Ctr, Winchester, VA USA
[3] Shenandoah Univ, Bernard J Dunn Sch Pharm, Dept Pharmacogen, Winchester, VA 22601 USA
[4] Shenandoah Univ, Bernard J Dunn Sch Pharm, Dept Biopharmaceut Sci, Winchester, VA 22601 USA
来源：
HEART AND VESSELS | 2009年 / 24卷 / 02期
关键词：
Pharmacogenomics; Clopidogrel; Polymorphism; CYP3A; ATHEROTHROMBOTIC EVENTS; SEQUENCE VARIATIONS; INCREASED RISK; VARIABILITY; RESPONSIVENESS; RESISTANCE; INTERVENTION; POLYMORPHISM;
D O I：
10.1007/s00380-008-1085-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The presence of cytochrome P450 (CYP) variant alleles may reduce the activation of the prodrug clopidogrel to its active state. This research evaluated the frequency of variant alleles in the genes coding for CYP3A4, CYP3A5, CYP2C9, and CYP2C19 enzymes in patients on clopidogrel therapy and experiencing repeat acute coronary syndrome (ACS) compared to a control group with a matching ethnic composition. Real-time polymerase chain reaction was used for allelic discrimination. Complete data were obtained for 92 patients enrolled over a 3-month period. There were no significant differences in the presence of the examined CYP3A4, CYP3A5, CYP2C9, or CYP2C19 variant alleles between the two groups. The present data indicate that patients currently receiving clopidogrel therapy who present with repeat ACS do not have higher frequency of the examined variant alleles compared to a control group.
引用
收藏
页码：73 / 78
页数：6
相关论文
共 23 条
[1]   Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel [J].
Angiolillo, Dominick J. ;
Fernandez-Ortiz, Antonio ;
Bernardo, Esther ;
Ramirez, Celia ;
Cavallari, Ugo ;
Trabetti, Elisabetta ;
Sabate, Manel ;
Hernandez, Rosana ;
Moreno, Raul ;
Escaned, Javier ;
Alfonso, Fernando ;
Banuelos, Camino ;
Costa, Marco A. ;
Bass, Theodore A. ;
Pignatti, Pier Franco ;
Macaya, Carlos .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (08) :1895-1900
[2]   Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty [J].
Bilsel, T ;
Akbulut, T ;
Yesilcimen, K ;
Terzi, S ;
Sayar, N ;
Dayi, SU ;
Akgoz, H ;
Ergelen, M ;
Ciloglu, F .
HEART AND VESSELS, 2006, 21 (02) :102-107
[3]  
Fisher AA, 2001, ANN PHARMACOTHER, V35, P1567
[4]   Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity [J].
Gurbel, PA ;
Bliden, KP ;
Hiatt, BL ;
O'Connor, CM .
CIRCULATION, 2003, 107 (23) :2908-2913
[5]  
Hsieh FY, 1998, STAT MED, V17, P1623, DOI 10.1002/(SICI)1097-0258(19980730)17:14<1623::AID-SIM871>3.0.CO
[6]  
2-S
[7]   Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects [J].
Hulot, Jean-Sebastien ;
Bura, Alessandra ;
Villard, Eric ;
Azizi, Michel ;
Remones, Veronique ;
Goyenvalle, Catherine ;
Aiach, Martine ;
Lechat, Philippe ;
Gaussem, Pascale .
BLOOD, 2006, 108 (07) :2244-2247
[8]  
Kidd R, 2006, J CLIN PHARMACOL, V46, P1085
[9]   The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance [J].
Kim, K. A. ;
Park, P. W. ;
Hong, S. J. ;
Park, J-Y .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (02) :236-242
[10]   Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance [J].
Lau, WC ;
Gurbel, PA ;
Watkins, PB ;
Neer, CJ ;
Hopp, AS ;
Carville, DGM ;
Guyer, KE ;
Tait, AR ;
Bates, ER .
CIRCULATION, 2004, 109 (02) :166-171
123